IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Analyst Ratings
USA - NASDAQ:IOVA - US4622601007 - Common Stock
1.795 USD
-0.03 (-1.37%)
ChartMill assigns a Buy % Consensus number of 76% to IOVA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 9.28. This target is 417.1% above the current price.
IOVA was analyzed by 18 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about IOVA.
In the previous month the buy percentage consensus was at a similar level.
IOVA was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-23 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-16 | UBS | Downgrade | Buy -> Neutral |
| 2025-05-12 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-12 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-12 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-14 | Barclays | Maintains | Overweight -> Overweight |
| 2025-03-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-03 | Truist Securities | Maintains | Buy -> Buy |
| 2025-03-03 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-02-28 | Baird | Maintains | Outperform -> Outperform |
| 2025-02-28 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-31 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | UBS | Initiate | Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-29 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-06-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-06-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
IOVANCE BIOTHERAPEUTICS INC / IOVA FAQ
Can you provide the average price target for IOVANCE BIOTHERAPEUTICS INC stock?
18 analysts have analysed IOVA and the average price target is 9.28 USD. This implies a price increase of 417.1% is expected in the next year compared to the current price of 1.795.
How do analysts rate IOVANCE BIOTHERAPEUTICS INC (IOVA)?
The consensus rating for IOVANCE BIOTHERAPEUTICS INC (IOVA) is 75.5556 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for IOVA stock?
The number of analysts covering IOVANCE BIOTHERAPEUTICS INC (IOVA) is 18.